The device monitors the diffusion of proteins as they flow through a microfluidic channel and allows the study of protein aggregation and interactions.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.
